These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18834108)

  • 1. Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium.
    Bolstad DB; Bolstad ES; Frey KM; Wright DL; Anderson AC
    J Med Chem; 2008 Nov; 51(21):6839-52. PubMed ID: 18834108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis.
    Pelphrey PM; Popov VM; Joska TM; Beierlein JM; Bolstad ES; Fillingham YA; Wright DL; Anderson AC
    J Med Chem; 2007 Mar; 50(5):940-50. PubMed ID: 17269758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two crystal structures of dihydrofolate reductase-thymidylate synthase from Cryptosporidium hominis reveal protein-ligand interactions including a structural basis for observed antifolate resistance.
    Anderson AC
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2005 Mar; 61(Pt 3):258-62. PubMed ID: 16511011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screen.
    Martucci WE; Udier-Blagovic M; Atreya C; Babatunde O; Vargo MA; Jorgensen WL; Anderson KS
    Bioorg Med Chem Lett; 2009 Jan; 19(2):418-23. PubMed ID: 19059777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the crossover helix impairs dihydrofolate reductase activity in the bifunctional enzyme TS-DHFR from Cryptosporidium hominis.
    Vargo MA; Martucci WE; Anderson KS
    Biochem J; 2009 Feb; 417(3):757-64. PubMed ID: 18851711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
    Senkovich O; Schormann N; Chattopadhyay D
    Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
    Nelson RG; Rosowsky A
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase.
    Liu J; Bolstad DB; Smith AE; Priestley ND; Wright DL; Anderson AC
    Chem Biol; 2008 Sep; 15(9):990-6. PubMed ID: 18804036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
    Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
    J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
    Kumar VP; Cisneros JA; Frey KM; Castellanos-Gonzalez A; Wang Y; Gangjee A; White AC; Jorgensen WL; Anderson KS
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4158-61. PubMed ID: 25127103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.
    Brophy VH; Vasquez J; Nelson RG; Forney JR; Rosowsky A; Sibley CH
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1019-28. PubMed ID: 10722506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of human dihydrofolate reductase activity and expression.
    Abali EE; Skacel NE; Celikkaya H; Hsieh YC
    Vitam Horm; 2008; 79():267-92. PubMed ID: 18804698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.
    Raimondi MV; Randazzo O; La Franca M; Barone G; Vignoni E; Rossi D; Collina S
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30909399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads.
    Joska TM; Anderson AC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3435-43. PubMed ID: 17005826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
    Srinivasan B; Tonddast-Navaei S; Skolnick J
    Eur J Med Chem; 2015 Oct; 103():600-14. PubMed ID: 26414808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Coxiela burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation.
    de Souza FR; Guimarães AP; Cuya T; de Freitas MP; Gonçalves ADS; Forgione P; Costa França TC
    J Biomol Struct Dyn; 2017 Oct; 35(13):2975-2986. PubMed ID: 27726597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivative.
    Popov VM; Chan DC; Fillingham YA; Atom Yee W; Wright DL; Anderson AC
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4366-70. PubMed ID: 16750361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.